Literature DB >> 29882618

Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists.

Javed Butler1, Shilpa Vijayakumar1, Bertram Pitt2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29882618      PMCID： PMC6125193          DOI： 10.1002/ejhf.1217

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  24 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

3.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

4.  Serum Potassium Levels and Outcome in Patients With Chronic Heart Failure.

Authors:  Sarah Hoss; Yair Elizur; David Luria; Andre Keren; Chaim Lotan; Israel Gotsman
Journal:  Am J Cardiol       Date:  2016-09-15       Impact factor: 2.778

5.  Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes.

Authors:  Allan J Collins; Bertram Pitt; Nancy Reaven; Susan Funk; Karen McGaughey; Daniel Wilson; David A Bushinsky
Journal:  Am J Nephrol       Date:  2017-09-02       Impact factor: 3.754

6.  Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.

Authors:  Orly Vardeny; Brian Claggett; Inder Anand; Patrick Rossignol; Akshay S Desai; Faiez Zannad; Bertram Pitt; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2014-05-08       Impact factor: 8.790

7.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

8.  Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).

Authors:  Patrick Rossignol; Daniela Dobre; John J V McMurray; Karl Swedberg; Henry Krum; Dirk J van Veldhuisen; Harry Shi; Michael Messig; John Vincent; Nicolas Girerd; George Bakris; Bertram Pitt; Faiez Zannad
Journal:  Circ Heart Fail       Date:  2013-12-02       Impact factor: 8.790

9.  How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

Authors:  Morten Svensson; Finn Gustafsson; Søren Galatius; Per R Hildebrandt; Dan Atar
Journal:  J Card Fail       Date:  2004-08       Impact factor: 5.712

10.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983
View more
  4 in total

Review 1.  Medical Therapy of Heart Failure with Reduced Ejection Fraction-A Call for Comparative Research.

Authors:  Gad Cotter; Beth A Davison; Alexandre Mebazaa; Koji Takagi; Maria Novosadova; Yonathan Freund; Alain Cohen-Solal
Journal:  J Clin Med       Date:  2021-04-21       Impact factor: 4.241

2.  New treatments for hyperkalaemia: clinical use in cardiology.

Authors:  Shilpa Vijayakumar; Javed Butler; Stefan D Anker
Journal:  Eur Heart J Suppl       Date:  2019-02-26       Impact factor: 1.803

Review 3.  Highlights in heart failure.

Authors:  Daniela Tomasoni; Marianna Adamo; Carlo Mario Lombardi; Marco Metra
Journal:  ESC Heart Fail       Date:  2019-12

4.  Renal function, electrolytes, and congestion monitoring in heart failure.

Authors:  Patrick Rossignol; Andrew Js Coats; Ovidiu Chioncel; Ilaria Spoletini; Giuseppe Rosano
Journal:  Eur Heart J Suppl       Date:  2019-12-31       Impact factor: 1.803
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.